Article
Ruhsatlandırma hazırlığının ötesinde Bolar: AB İlaç Paketi, Türkiye’nin deneyimi ve TRIPS’e uygunluk
The European Commission's proposed EU Pharmaceutical Package significantly expands the Bolar exemption beyond traditional regulatory approval activities to include pricing, reimbursement, health technology assessments, and public procurement participation. This expansion raises critical questions about whether such broad exceptions remain compatible with TRIPS Article 30 requirements, particularly when commercial activities like tender submissions may constitute offers for sale rather than purely regulatory

Gün + Partners










